Audit: QRS - Vitamin K1 for Health & Longevity

Audit conducted on 11/08/2026 11:32 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All numeric magnitudes traced: 43.8%→18.0% (ER 148), 1–2.5 mg / INR <5 in 24 h (ER 154), 100–500 µg (ER 320), 5 mg 2–4 y (ER 322), 0.5 nmol/L (ER 338), all 8 marker targets (ER 400–407), cadence (ER 396).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“no demonstrated effect” (action_2_sub) mirrors ER 328; “associated with higher vitamin K1 status” retains the ER’s associational framing (ER 184).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Mortality benefit kept as association; “no interaction” for DOACs matches ER 294 exactly; contraindication scope unchanged.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications drawn from ER 296–300, Key Interactions from ER 276–294, Benefits from ER Expected Benefits, Risks from ER Potential Risks & Side Effects. No cross-category migration.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, expert names, or brand names appear anywhere in the QRS; “ECKO” was correctly dropped in action_1_sub.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Declarative, evidence-first register matching the ER throughout.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Numeric magnitudes paired with plain-language framing in at_a_glance and protocol cells.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	States what trials and markers show; no imperatives.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No “should”, “take”, or “consult” constructions in the QRS’s own voice.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Protocol cells report the studied dose, timing, and baseline marker rather than prescribing them.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns present (verified by search).
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms retained only where they are the marker names the ER itself uses (dp-ucMGP, PIVKA-II, INR).
2.8	Information is presented in a concise and very compact manner	🟢	Every ER bullet reduced to a phrase or single clause; protocol subs are at most two short sentences.
2.9	It DOES NOT address the reader directly	🟢	Confirmed; no direct address anywhere in the document.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content assumes willingness to test plasma phylloquinone, dp-ucMGP, calcium score, and DEXA.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Multi-year horizon and structural-imaging monitoring presented without hedging on effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Functional carboxylation markers and three-year endpoint expectations are beyond general-population framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	at_a_glance states the negative supplement-trial record plainly, and action_3 flags that well-carboxylated individuals have little to gain.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Clinical register maintained (“anaphylactoid”, “coagulopathy”, “supratherapeutic INR”); the sole plain phrase “blood thinners” sits in at_a_glance, where item 7.4 requires plain-language substitution, and is the ER’s own wording (ER 440).

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All present verbatim at lines 446, 492, 543, 575, 594, 615, 640, 644–646, 770; tier labels at 547, 553, 559, 565, 618, 621, 625, 631.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 33 distinct template variables present; the repeatable marker_#/qualitative_item_# rows are instantiated as marker_1–8 and qualitative_item_1–4.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Structural diff against the template shows changes confined to variable content; CSS, comments, footer, and markup structure are byte-identical.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section mapped into the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard dose range” (ER 320), “Best time of day” (ER 328), “Baseline biomarkers” (ER 338) carried over verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Marker names verbatim from the ER table (ER 400–407); time-row labels use the ER’s own wording (ER 370, 150).
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Zero emoji in the file; the ER’s ⚠️ Conflicted markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Each oversized ER section was condensed rather than carried over: 12 Protocol bullets → 3 cells, multi-sentence risk/benefit entries → single clauses, qualitative markers stripped of their trailing rationale.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype at line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” at line 3, closing at line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the header or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly, because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: vitamin_k1_2026-0811-0941_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0811-1129.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s actual name.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Verified across all nine keys; no stray whitespace or quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Vitamin K1 for Health & Longevity - Quick Reference Sheet”; matches ER canonical_topic (ER 8) with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Vitamin K1 for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/11/2026, from qrs_creation_date 2026-0811-1129.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the template subline; the ER’s “Also known as” line (ER 30) was correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses all four Conclusion paragraphs (ER 436–442): biochemical effect, negative trial record, favorable safety, anticoagulant hazard.
7.2	[at_a_glance] is no longer than 60 words	🟢	57 tokens / 56 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Leafy greens (ER 436), carboxylation switch-on (ER 436), longer life in observational data (ER 438), negative bone/fracture/calcium trials (ER 438), favorable safety (ER 440), cancels blood thinners (ER 440).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “calcium-handling proteins” and “blood thinners” replace the technical terms used elsewhere.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year, or sample size appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All three items map to the “Populations who should avoid Vitamin K1” list (ER 298–300).
8.2	[stop_items] represent the Contraindications from the ER	🟢	3 ER entries → 3 QRS items, complete and one-to-one.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 578–589: three <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	No dashes or trailing clauses; ER’s “Anyone taking…, particularly with” reduced to the bare fact plus its parenthetical.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Target INR 2.5–3.5, the 3-month VTE window, and the injected-vs-oral scope qualifier are all preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in the contraindication list.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names three such populations and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items map to ER 278–294.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	10 ER interaction bullets → 9 items; the vitamin K antagonist bullet (ER 276) is correctly omitted because it appears as contraindication 1.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 597–605: nine <li> elements.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER mechanism and mitigation clause stripped; the only retained tails (“additive”, “no interaction”) are the interaction class itself, without which the item would misstate the ER.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named drug lists retained for orlistat, sequestrants, anticonvulsants, K2 forms, bleeding-risk supplements, and DOACs; the 800 IU vitamin E threshold retained.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in the interaction list.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER identifies ten; the section is populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to ER Therapeutic Protocol bullets at lines 320, 322, 328, 338.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, administration timing, and the baseline test that decides whether to start — the three decisions the ER’s own protocol turns on.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies eleven protocol bullets; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine variables populated; none carry placeholder text.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Carboxylation markers (ER 370), coagulopathy correction (ER 152/154), vascular and skeletal endpoints (ER 370/346).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Sets 1 and 2 map to the two High-tier benefits in ER order; set 3 maps to the Medium/Low vascular and skeletal endpoints.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct aspects exist; all sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine variables populated with ER-sourced content and magnitudes.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (ER 370), so the section is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All ten benefit headings from ER 144–202 are represented in the matching tier.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four present at lines 545, 551, 557, 563, each in its correct tier.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry reduced to the ER heading; no Magnitude line, trial name, or mechanism carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	The ER’s “(Impaired Blood Clotting)” gloss (ER 150) is correctly stripped; no parentheses remain in any tier.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers contain items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All six risk headings from ER 224–260 are represented in the matching tier.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four present at lines 617, 620, 623, 629, each in its correct tier.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	The 3-per-10,000 incidence, the castor-oil solubilizer mechanism, and the 1992 case-control detail are all omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	The ER’s “(anaphylaxis-like)” and “(an inherited tendency to clot)” glosses are stripped; no parentheses remain.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers contain items in the ER.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Rows correspond one-to-one with the ER biomarker table (ER 398–407).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 8 ER biomarkers present with names, targets, and rationale carried over verbatim; none dropped.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 760 reproduces the ER’s cadence paragraph (ER 396): 4 weeks, 3 months, 6–12 months, 2–3 years.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All four items map to the ER’s “Qualitative markers worth tracking” list (ER 411–414).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	4 ER entries → 4 QRS items: bruising/bleeding, leg cramps, gum bleeding, digestive tolerance.

Issues 11/08/2026 11:32

Pass rate 100.00%. No issues found.